Common plasma protein marker LCAT in aggressive human breast cancer and canine mammary tumor

• Published in: BMB reports Vol. 53; no. 12; pp. 664 - 669
• Main Authors: Park, Hyoung-Min, Kim, HuiSu, Kim, Dong Wook, Yoon, Jong-Hyuk, Kim, Byung-Gyu, Cho, Je-Yoel
• Format: Journal Article
• Language: Korean
• Published: 생화학분자생물학회 31.12.2020
• Subjects: Biomarker; Breast cancer; Comparative medicine; Prognostic; Proteomics; Biomarker; Breast cancer; Comparative medicine; Prognostic; Proteomics
• ISSN: 1976-6696; 1976-670X

Breast cancer is one of the most frequently diagnosed cancers. Although biomarkers are continuously being discovered, few specific markers, rather than classification markers, representing the aggressiveness and invasiveness of breast cancer are known. In this study, we used samples from canine mammary tumors in a comparative approach. We subjected 36 fractions of both canine normal and mammary tumor plasmas to highperformance quantitative proteomics analysis. Among the identified proteins, LCAT was selectively expressed in mixed tumor samples. With further MRM and Western blot validation, we discovered that the LCAT protein is an indicator of aggressive mammary tumors, an advanced stage of cancer, possibly highly metastatic. Interestingly, we also found that LCAT is overexpressed in high-grade and lymph-node-positive breast cancer in silico data. We also demonstrated that LCAT is highly expressed in the sera of advanced-stage human breast cancers within the same classification. In conclusion, we identified a possible common plasma protein biomarker, LCAT, that is highly expressed in aggressive human breast cancer and canine mammary tumor. [BMB Reports 2020; 53(12): 664-669]